Revolax Sub-Q

Revolax Sub-Q with Lidocaine

Revolax Sub-Q with Lidocaine is a monophasic cross-linked hyaluronic acid (HA) dermal filler from Across Co., Ltd., South Korea. It is the most viscous and firmest gel in the Revolax range, designed for deep subcutaneous injection to correct deep to severe wrinkles and folds and to add volume and contour to the cheeks and chin. It contains 24 mg/ml cross-linked HA and 0.3% lidocaine hydrochloride. Each box contains one 1.1 ml pre-filled syringe. For use by licensed physicians only.

Key Features

• Firmest Gel in the Range: The most viscous Revolax gel, intended for deep subcutaneous placement where shape retention is needed.
• Monophasic Gel: A uniform, cohesive cross-linked HA gel, designed for consistent extrusion.
• HA 24 mg/ml: Non-animal hyaluronic acid produced by bacterial fermentation, cross-linked with BDDE.
• With 0.3% Lidocaine: Included to help reduce discomfort during injection.
• Reversible: Hyaluronic acid can be dissolved with hyaluronidase by a qualified practitioner.

The Revolax Range

The Revolax range includes three gels of increasing firmness. The physician selects the product according to the treatment area, tissue depth and desired result.

• Revolax Fine: The softest gel, for fine lines in the superficial dermis.
• Revolax Deep: A medium-firm gel for moderate to deep wrinkles and folds and lip volume, in the deep dermis or subcutaneous tissue.
• Revolax Sub-Q: The firmest gel, for deep to severe folds and deep subcutaneous volume and contour.

Intended Use

• Deep to severe wrinkles and folds
• Nasolabial folds
• Cheek volume and contour
• Chin volume and contour

Treatment area, injection depth, technique and volume must follow the official Instructions for Use and the treating physician’s assessment. Results and duration vary between individuals.

Product Specifications

• Brand: Revolax™
• Product: Revolax Sub-Q with Lidocaine
• Manufacturer: Across Co., Ltd.
• Origin: South Korea
• Composition: Cross-linked hyaluronic acid 24 mg/ml, lidocaine hydrochloride 3 mg/ml (0.3%), phosphate-buffered saline
• Gel Type: Monophasic, BDDE cross-linked
• Injection Depth: Deep subcutaneous, as specified in the IFU
• Needle: 25G
• Contents: 1 × 1.1 ml pre-filled syringe, 2 × 25G needles
• Shelf Life: Refer to the carton for the expiry date
• Product Type: Hyaluronic acid dermal filler (medical device)

Administration

• For use only by licensed physicians trained in facial anatomy, filler injection techniques and the management of filler complications.
• Inject under aseptic conditions into the deep subcutaneous tissue.
• Not intended for superficial injection, the eye area or the lips. Softer gels in the range are designed for these uses.
• Do not mix with other products before injection.
• If the needle becomes blocked, do not increase pressure on the plunger. Stop the injection and replace the needle.
• Injection depth, technique, volume and treatment interval must follow the IFU and the treating physician’s judgment.
• Do not self-administer.

Precautions

• Common reactions include redness, swelling, pain, tenderness, itching and bruising at the injection site.
• Lumps, nodules, palpable or visible product, asymmetry, infection and delayed inflammatory reactions may occur.
• Accidental injection into a blood vessel can cause vascular occlusion, skin necrosis and, rarely, visual impairment or blindness.
• Contains lidocaine. Not suitable for people with known allergy to lidocaine or other amide-type local anaesthetics.
• Do not inject into areas with an existing implant, or with skin inflammation or infection.
• Do not combine in the same session with laser treatment, chemical peels or dermabrasion.
• Hyaluronic acid products are incompatible with quaternary ammonium salts such as benzalkonium chloride.
• Hyaluronic acid can be dissolved with hyaluronidase. Practitioners should keep hyaluronidase and an emergency protocol available.
• Seek medical attention immediately for severe or increasing pain, skin blanching or colour change, or any change in vision after treatment.
• Do not use if the packaging is open or damaged, the syringe is cracked or the product is past its expiry date.
• Single use only. One syringe, one patient. Do not re-sterilise. Keep out of reach of children.

Who Should Consult a Physician First

• People with known allergy to hyaluronic acid, lidocaine or amide-type local anaesthetics
• Pregnant or breastfeeding women
• People with infection, inflammation or skin disease at the treatment area
• People with bleeding disorders, or who have taken anticoagulants or platelet inhibitors in the previous 2 weeks
• People taking aspirin, NSAIDs or high-dose vitamin C (the IFU recommends avoiding these in the week before injection)
• People with autoimmune disease, a tendency to hypertrophic scars or keloids, or severe allergies
• People with permanent fillers or implants in the treatment area
• People under 18 years of age

After Treatment

As advised in the IFU, avoid make-up for 12 hours after injection, and avoid prolonged exposure to sun, UV, extreme cold and extreme heat for two weeks. Follow the treating physician’s aftercare instructions.

Storage

Store at 2–25°C. Protect from direct sunlight and freezing. Refer to the carton for the expiry date.

Package Contents

• 1 × 1.1 ml pre-filled syringe of Revolax Sub-Q with Lidocaine
• 2 × 25G needles
• Instructions for Use

Important Notice

For professional healthcare use only. This information is for general product reference. It does not replace medical advice, the official Instructions for Use or local regulations. This product is not intended to diagnose, treat, cure or prevent any disease. Results vary between individuals.